BR112014008082A8 - uso de aminopiridina ou de sais da mesma para fabricação de medicamentos para tratar deterioração relacionada com acidente vascular cerebral - Google Patents

uso de aminopiridina ou de sais da mesma para fabricação de medicamentos para tratar deterioração relacionada com acidente vascular cerebral

Info

Publication number
BR112014008082A8
BR112014008082A8 BR112014008082A BR112014008082A BR112014008082A8 BR 112014008082 A8 BR112014008082 A8 BR 112014008082A8 BR 112014008082 A BR112014008082 A BR 112014008082A BR 112014008082 A BR112014008082 A BR 112014008082A BR 112014008082 A8 BR112014008082 A8 BR 112014008082A8
Authority
BR
Brazil
Prior art keywords
aminopyridine
medicines
salts
manufacture
treat stroke
Prior art date
Application number
BR112014008082A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014008082A2 (pt
Inventor
R Blight Andrew
O Caggiano Anthony
F Iaci Jennifer
J Parry Tom
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of BR112014008082A2 publication Critical patent/BR112014008082A2/pt
Publication of BR112014008082A8 publication Critical patent/BR112014008082A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
BR112014008082A 2011-10-04 2012-10-04 uso de aminopiridina ou de sais da mesma para fabricação de medicamentos para tratar deterioração relacionada com acidente vascular cerebral BR112014008082A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US201261648695P 2012-05-18 2012-05-18
PCT/US2012/058607 WO2013052575A1 (en) 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines

Publications (2)

Publication Number Publication Date
BR112014008082A2 BR112014008082A2 (pt) 2017-07-18
BR112014008082A8 true BR112014008082A8 (pt) 2018-01-16

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008082A BR112014008082A8 (pt) 2011-10-04 2012-10-04 uso de aminopiridina ou de sais da mesma para fabricação de medicamentos para tratar deterioração relacionada com acidente vascular cerebral

Country Status (22)

Country Link
US (2) US20130085167A1 (https=)
EP (1) EP2766017B1 (https=)
JP (1) JP6134722B2 (https=)
KR (1) KR20140084120A (https=)
CN (2) CN104220072B (https=)
AR (1) AR088764A1 (https=)
AU (2) AU2012318719B2 (https=)
BR (1) BR112014008082A8 (https=)
CA (1) CA2850635A1 (https=)
CL (1) CL2014000799A1 (https=)
CO (1) CO7061067A2 (https=)
CR (1) CR20140153A (https=)
EA (1) EA029558B1 (https=)
HK (1) HK1201204A1 (https=)
IL (1) IL231809B (https=)
MX (1) MX354667B (https=)
PH (1) PH12014500739B1 (https=)
SG (2) SG11201401248YA (https=)
TW (1) TWI592156B (https=)
UA (1) UA114486C2 (https=)
WO (1) WO2013052575A1 (https=)
ZA (1) ZA201402432B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1221666A1 (zh) * 2013-04-15 2017-06-09 Acorda Therapeutics, Inc. 氨基吡啶用於治疗与某些中风类型相关的视觉障碍的方法
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、系统及设备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
JPH03505868A (ja) * 1988-04-08 1991-12-19 マサチユセツツ・インスチチユート・オブ・テクノロジー 神経性疾患を治療するための方法及び組成物
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
EP1152760B1 (en) * 1999-02-09 2007-03-28 UAB Research Foundation Use of 4-amino pyridine for treatment of peripheral neuropathies
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
AU2001242184A1 (en) * 2000-03-28 2001-10-08 Queen:S University At Kingston Methods for effecting neuroprotection using a potassium channel modulator
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス,インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用

Also Published As

Publication number Publication date
EA201490562A1 (ru) 2014-08-29
CN104220072B (zh) 2018-04-17
HK1204965A1 (en) 2015-12-11
NZ623255A (en) 2016-08-26
CA2850635A1 (en) 2013-04-11
TW201321000A (zh) 2013-06-01
EA029558B1 (ru) 2018-04-30
MX354667B (es) 2018-03-15
CO7061067A2 (es) 2014-09-19
HK1201204A1 (en) 2015-08-28
SG10201600410SA (en) 2016-02-26
KR20140084120A (ko) 2014-07-04
BR112014008082A2 (pt) 2017-07-18
EP2766017B1 (en) 2020-07-01
AR088764A1 (es) 2014-07-02
AU2012318719B2 (en) 2017-10-19
CN104220072A (zh) 2014-12-17
ZA201402432B (en) 2020-08-26
US20160067232A1 (en) 2016-03-10
JP6134722B2 (ja) 2017-05-24
PH12014500739A1 (en) 2014-05-26
SG11201401248YA (en) 2014-05-29
TWI592156B (zh) 2017-07-21
PH12014500739B1 (en) 2019-05-10
US20130085167A1 (en) 2013-04-04
EP2766017A1 (en) 2014-08-20
CN108451953A (zh) 2018-08-28
CL2014000799A1 (es) 2014-11-03
UA114486C2 (uk) 2017-06-26
WO2013052575A1 (en) 2013-04-11
AU2018200114A1 (en) 2018-01-25
MX2014003997A (es) 2014-07-22
IL231809A0 (en) 2014-05-28
CR20140153A (es) 2014-07-04
JP2014531470A (ja) 2014-11-27
IL231809B (en) 2019-06-30
AU2012318719A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
PT2852391T (pt) Sistemas para tratamento de infeções pulmonares
BR112013033444A2 (pt) formulações para terapia de ferida
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
CO7020879A2 (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
PT3321276T (pt) Proteínas de fusão para o tratamento de distúrbios metabólicos
BR112014005914A2 (pt) Produto para cicatrização de feridas tecidulares
BR112013018852A2 (pt) Derivados do tipo azaindazol ou diazaindazol como medicamento
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
BR112013033974A2 (pt) terapia de combinação
PT2838539T (pt) Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos.
PT2768859T (pt) Antagonistas de il17c para o tratamento de desordens inflamatórias
IL231622B (en) Pharmaceutical composition for treatment of cachexia
EP2783256A4 (en) Therapeutic eyewear
BRDI7105383S (pt) Configuração aplicada em banda de rodagem para pneumático
IL229081A0 (en) Isoxazolines as therapeutic agents
BRDI7105384S (pt) Configuração aplicada em banda de rodagem para pneumático
CO7020857A2 (es) Procedimiento para la preparación de complejos de 68ga

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements